Balchem Corp: Form 10-Q for the period ended Jun 30, 2020
Filed with the SEC on Jul 31, 2020 and accepted by EDGAR at Jul 31, 2020, 13:18 ET.
Management's discussion and analysis
As filed, 25,003 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
This report contains forward-looking statements, within the meaning of Section 21E of the Exchange Act, which reflect our expectation or belief concerning future events that involve risks and uncertainties. Actions and performance could differ materially from what is contemplated by the forward-looking statements contained in this report. Factors that might cause differences from the forward-looking statements include those referred to or identified in Item 1A of the Annual Report on Form 10-K for the year ended December 31, 2019 and other factors that may be identified elsewhere in this report. Reference should be made to such factors and all forward-looking statements are qualified in their entirety by the above cautionary statements.
Overview
We develop, manufacture, distribute and market specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. Previously, our four reportable segments were: Human Nutrition and Health, Animal Nutrition and Health, Specialty Products, and Industrial Products. However, effective in the first quarter of 2020, in order to align with our strategic focus on health and nutrition, allocation of resources, and evaluation of operating performance, and given the 2019 reduction in portfolio scale of Industrial Products, we have revised our reporting segment structure to three reportable segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. These reportable segments are strategic businesses that offer products and services to different markets. This realignment has been retrospectively applied. Sales and production of products outside of our reportable segments and other minor business activities are included in "Other and Unallocated" and applied retroactively to 2019. There was no change to the Consolidated Financial Statements as a result of the change to the reportable segments. We expect that the new reportable segment structure will provide investors greater understanding of and alignment with our strategic focus. In order to ensure appropriate transparency and visibility into the financial performance of the Company, sufficient detail will continue to be provided relative to Other and Unallocated, including material contributions from oil and gas and other industrial market activities.
COVID-19 Response
The COVID-19 response effort has been a primary focus for us since early in the first quarter. Our focus has been on employee safety first, keeping our manufacturing sites operational, satisfying customer needs, preserving cash and ensuring strong liquidity, and responding to changes in this dynamic market environment as appropriate. To date, all of our manufacturing sites are operating at near normal conditions enabling us to supply our customers with the important products and services they need, our research and development teams are advancing our innovation efforts, and all of our other employees are effectively carrying on their responsibilities and functions remotely.
While impact on demand in the first two quarters was not material to our Company, we are continuing to watch the markets that we serve closely. We have stress tested our balance sheet under various significant downturn scenarios and, given our relatively low net debt position, cash on hand, access to our undrawn revolving credit facility, and expected free cash flows, we are pleased with the strength of our balance sheet as we continue through this uncertain market environment. Despite this relative strength, we are continuing to take actions to reduce capital expenditures and non-critical cash expenses wherever possible to preserve cash.
We elected to pause activities related to our global enterprise resource planning ("ERP") implementation project during the second quarter. Travel restrictions and border closures imposed by governments to mitigate COVID-19 contagion made it impossible to provide on-the-ground support at the times of go-lives previously planned for the second quarter and early in the third quarter. For these reasons, we have chosen to refocus our employees on optimization of the new ERP for sites that have already gone live, while navigating through this period of volatility and uncertainty.
Segment Results
We sell products for all three segments through our own sales force, independent distributors, and sales agents.
The following tables summarize consolidated net sales by segment and business segment earnings from operations for the three and six months ended June 30, 2020 and 2019:
| Business Segment Net Sales | Three Months Ended June 30, 2020 | 2019 | Six Months Ended June 30, 2020 | 2019 |
|---|---|---|---|---|
| Human Nutrition & Health | $97,428 | $85,872 | $192,936 | $171,021 |
| Animal Nutrition & Health | 46,344 | 43,480 | 94,985 | 86,841 |
| Specialty Products | 28,194 | 24,907 | 56,190 | 43,331 |
| Other and Unallocated (1) | 1,389 | 7,295 | 3,680 | 17,390 |
| Total | $173,355 | $161,554 | $347,791 | $318,583 |
| Business Segment Earnings From Operations | Three Months Ended June 30, 2020 | 2019 | Six Months Ended June 30, 2020 | 2019 |
|---|---|---|---|---|
| Human Nutrition & Health | $15,497 | $12,338 | $27,632 | $26,041 |
| Animal Nutrition & Health | 6,430 | 5,045 | 14,474 | 10,301 |
| Specialty Products | 8,008 | 8,879 | 15,994 | 15,576 |
| Other and Unallocated (1) | (3,018) | 140 | (4,905) | 964 |
| Total | $26,917 | $26,402 | $53,195 | $52,882 |
(1) Other and Unallocated consists of a few minor businesses which individually do not meet the quantitative thresholds for separate presentation and corporate expenses that have not been allocated to a segment. Unallocated corporate expenses consist of: (i) Transaction and integration costs, ERP implementation costs, and unallocated legal fees totaling $746 and $2,018 for the three and six months ended June 30, 2020, respectively, and $761 and $1,565 for the three and six months ended June 30, 2019, respectively, and (ii) Unallocated amortization expense of $405 and $806 for the three and six months ended June 30, 2020, respectively, and $10 and $19 for the three and six months ended June 30, 2019, respectively, related to an intangible asset in connection with a company-wide ERP system implementation.
Acquisitions
On December 13, 2019, we acquired Zumbro. We made payments of $51,842 on the acquisition date, amounting to $46,497 to the former shareholders and $5,345 to Zumbro's lenders to pay Zumbro debt. Considering the cash acquired of $686, net payments made to the former shareholders were $45,811. In May 2020, we received an adjustment for working capital acquired of $561. Zumbro is integrated within the HNH Segment.
On May 27, 2019, we acquired Chemogas. We made payments of approximately €99,503 (translated to $111,324) on the acquisition date, amounting to approximately €88,579 (translated to $99,102) to the former shareholders and approximately €10,924 (translated to $12,222) to Chemogas' lender to pay off all Chemogas bank debt. Considering the cash acquired of €3,943 (translated to $4,412), net payments made to the former shareholders were €84,636 (translated to $94,690). Chemogas is integrated within the Specialty Products Segment.
RESULTS OF OPERATIONS
(All amounts in thousands, except share and per share data)
Three months ended June 30, 2020 compared to three months ended June 30, 2019.
Net Earnings
(in thousands)
| Three Months Ended June 30, 2020 | 2019 | Increase (Decrease) % Change | ||
|---|---|---|---|---|
| Net sales | $173,355 | $161,554 | $11,801 | 7.3% |
| Gross margin | 55,380 | 53,918 | 1,462 | 2.7% |
| Operating expenses | 28,463 | 27,516 | 947 | 3.4% |
| Earnings from operations | 26,917 | 26,402 | 515 | 2.0% |
| Other expenses | 944 | 1,521 | (577) | (37.9)% |
| Income tax expense | 4,848 | 5,052 | (204) | (4.0)% |
| Net earnings | $21,125 | $19,829 | $1,296 | 6.5% |
Net Sales
(in thousands)
| Three Months Ended June 30, 2020 | 2019 | Increase (Decrease) % Change | ||
|---|---|---|---|---|
| HNH | $97,428 | $85,872 | $11,556 | 13.5% |
| ANH | 46,344 | 43,480 | 2,864 | 6.6% |
| Specialty Products | 28,194 | 24,907 | 3,287 | 13.2% |
| Other | 1,389 | 7,295 | (5,906) | (81.0)% |
| Total | $173,355 | $161,554 | $11,801 | 7.3% |
- The increase in net sales within the HNH segment for the three months ended June 30, 2020 as compared to 2019 was primarily driven by strong sales growth of chelated minerals and choline nutrients as well as increased sales into the food and beverage markets from both the legacy business and the Zumbro acquisition we closed in December 2019, partially offset by lower sales to food service related markets and the elimination of sales associated with the Reading, Pennsylvania manufacturing site that we divested in 2019.
- The increase in net sales within the ANH segment for the three months ended June 30, 2020 compared to 2019 was primarily the result of higher volumes in both the ruminant species and monogastric species markets.
- The increase in Specialty Products segment sales for the three months ended June 30, 2020 compared to 2019 was primarily due to higher sales of ethylene oxide for the medical device sterilization market due to the incremental contribution of Chemogas, offset partially by lower legacy sales which were negatively impacted by reduced elective surgical procedures during the pandemic.
- Sales relating to business formerly included in the Industrial Products segment decreased from the prior year due to a decline in shale fracking activity.
Gross Margin
(in thousands)
| Three Months Ended June 30, 2020 | 2019 | Increase (Decrease) % Change | ||
|---|---|---|---|---|
| Gross margin | $55,380 | $53,918 | $1,462 | 2.7% |
| % of net sales | 31.9% | 33.4% |
Gross margin as a percentage of sales decreased for the three months ended June 30, 2020 compared to 2019 primarily due to mix and certain COVID-19 expenses, partially offset by certain lower raw material costs.
Operating Expenses
(in thousands)
| Three Months Ended June 30, 2020 | 2019 | Increase (Decrease) % Change | ||
|---|---|---|---|---|
| Operating expenses | $28,463 | $27,516 | $947 | 3.4% |
| % of net sales | 16.4% | 17.0% |
The increase in operating expenses was primarily due to incremental operating expenses related to the Chemogas and Zumbro acquisitions and a goodwill impairment charge related to business formerly included in the Industrial Products segment, partially offset by lower selling expenses driven by reduced travel and a decrease in bad debt expense.
Earnings from Operations
(in thousands)
| Three Months Ended June 30, 2020 | 2019 | Increase (Decrease) % Change | ||
|---|---|---|---|---|
| HNH | $15,497 | $12,338 | $3,159 | 25.6% |
| ANH | 6,430 | 5,045 | 1,385 | 27.5% |
| Specialty Products | 8,008 | 8,879 | (871) | (9.8)% |
| Other and unallocated | (3,018) | 140 | (3,158) | (2255.7)% |
| Earnings from operations | $26,917 | $26,402 | $515 | 2.0% |
| % of net sales (operating margin) | 15.5% | 16.3% |
- Earnings from operations for the HNH segment increased primarily due to the aforementioned higher sales and lower selling expenses principally due to lower travel and a decrease in bad debt expense.
- ANH segment earnings from operations increased primarily due to the aforementioned higher sales, certain lower raw material costs, and lower selling expenses principally due to lower travel.
- The decrease in earnings from operations for the Specialty Products segment was primarily due to lower legacy ethylene oxide sales, product mix within plant nutrition, and higher operating expenses due to the acquisition of Chemogas.
- The decrease in other and unallocated was driven primarily by lower earnings from the business formerly reported in the Industrial Products segment, as well as increased unallocated amortization related to a company-wide ERP implementation.
Other Expenses (Income)
(in thousands)
| Three Months Ended June 30, 2020 | 2019 | Increase (Decrease) % Change | ||
|---|---|---|---|---|
| Interest expense | $960 | $1,488 | $(528) | (35.5)% |
| Other, net | (16) | 33 | (49) | (148.5)% |
| $944 | $1,521 | $(577) | (37.9)% |
Interest expense for the three months ended June 30, 2020 and 2019 was primarily related to outstanding borrowings under our credit facility.
Income Tax Expense
(in thousands)
| Three Months Ended June 30, 2020 | 2019 | Increase (Decrease) % Change | ||
|---|---|---|---|---|
| Income tax expense | $4,848 | $5,052 | $(204) | (4.0)% |
| Effective tax rate | 18.7% | 20.3% |
The decrease of effective tax rate was mainly attributable to lower enacted tax rates from several states, certain higher tax credits, and excess tax benefits from stock-based compensation.
Six months ended June 30, 2020 compared to six months ended June 30, 2019.
Net Earnings
(in thousands)
| Six Months Ended June 30, 2020 | 2019 | Increase (Decrease) % Change | ||
|---|---|---|---|---|
| Net sales | $347,791 | $318,583 | $29,208 | 9.2% |
| Gross margin | 110,711 | 103,013 | 7,698 | 7.5% |
| Operating expenses | 57,516 | 50,131 | 7,385 | 14.7% |
| Earnings from operations | 53,195 | 52,882 | 313 | 0.6% |
| Other expenses | 2,732 | 3,208 | (476) | (14.8)% |
| Income tax expense | 9,570 | 11,062 | (1,492) | (13.5)% |
| Net earnings | $40,893 | $38,612 | $2,281 | 5.9% |
Net Sales
(in thousands)
| Six Months Ended June 30, 2020 | 2019 | Increase (Decrease) % Change | ||
|---|---|---|---|---|
| HNH | $192,936 | $171,021 | $21,915 | 12.8% |
| ANH | 94,985 | 86,841 | 8,144 | 9.4% |
| Specialty Products | 56,190 | 43,331 | 12,859 | 29.7% |
| Other | 3,680 | 17,390 | (13,710) | (78.8)% |
| Total | $347,791 | $318,583 | $29,208 | 9.2% |
- The increase in net sales within the HNH segment for the six months ended June 30, 2020 as compared to 2019 was primarily driven by strong sales growth of chelated minerals and choline nutrients as well as increased sales into the food and beverage markets from both the legacy business and the Zumbro acquisition we closed in December 2019, partially offset by lower sales to food service related markets and the elimination of sales associated with the Reading, PA manufacturing site that we divested in 2019.
- The increase in net sales within the ANH segment for the six months ended June 30, 2020 compared to 2019 was primarily the result of higher volumes in both the ruminant species and monogastric species markets.
- The increase in Specialty Products segment sales for the six months ended June 30, 2020 compared to 2019 was primarily driven by higher sales of ethylene oxide for the medical device sterilization market due to the incremental contribution of Chemogas and higher plant nutrition sales, offset partially by lower legacy ethylene oxides sales which were negatively impacted by reduced elective surgical procedures during the pandemic.
- Sales relating to business formerly included in the Industrial Products segment decreased from the prior year due to a decline in shale fracking activity.
Gross Margin
(in thousands)
| Six Months Ended June 30, 2020 | 2019 | Increase (Decrease) % Change | ||
|---|---|---|---|---|
| Gross margin | $110,711 | $103,013 | $7,698 | 7.5% |
| % of net sales | 31.8% | 32.3% |
Gross margin as a percentage of sales decreased for the six months ended June 30, 2020 compared to 2019 primarily due to mix, partially offset by certain lower raw material costs.
Operating Expenses
(in thousands)
| Six Months Ended June 30, 2020 | 2019 | Increase (Decrease) % Change | ||
|---|---|---|---|---|
| Operating expenses | $57,516 | $50,131 | $7,385 | 14.7% |
| % of net sales | 16.5% | 15.7% |
The increase in operating expenses was primarily due to incremental operating expenses related to the Chemogas and Zumbro acquisitions, the prior year benefiting from the timing of an insurance recovery, and a goodwill impairment charge related to business formerly included in the Industrial Products segment, partially offset by lower selling expenses driven by reduced travel.
Earnings from Operations
(in thousands)
| Six Months Ended June 30, 2020 | 2019 | Increase (Decrease) % Change | ||
|---|---|---|---|---|
| HNH | $27,632 | $26,041 | $1,591 | 6.1% |
| ANH | 14,474 | 10,301 | 4,173 | 40.5% |
| Specialty Products | 15,994 | 15,576 | 418 | 2.7% |
| Other and unallocated | (4,905) | 964 | (5,869) | (608.8)% |
| Earnings from operations | $53,195 | $52,882 | $313 | 0.6% |
| % of net sales (operating margin) | 15.3% | 16.6% |
- Earnings from operations for the HNH segment increased primarily due to the aforementioned higher sales and lower selling expenses due to reduced travel, partially offset by higher general and administrative expenses resulting from the prior year benefiting from the timing of an insurance recovery.
- ANH segment earnings from operations increased primarily due to the aforementioned higher sales, certain lower raw material costs, and lower selling expenses due to reduced travel.
- The increase in earnings from operations for the Specialty Products segment was primarily due to the aforementioned higher sales, partially offset by lower legacy ethylene oxide sales, product mix within plant nutrition, and higher operating expenses due to the acquisition of Chemogas.
- The decrease in other and unallocated was driven primarily by lower earnings from the business formerly reported in the industrial products segment, as well as increased transaction and integration costs and unallocated amortization related to a company-wide ERP implementation.
Other Expenses (Income)
(in thousands)
| Six Months Ended June 30, 2020 | 2019 | Increase (Decrease) % Change | ||
|---|---|---|---|---|
| Interest expense | $2,656 | $3,077 | $(421) | (13.7)% |
| Other, net | 76 | 131 | (55) | (42.0)% |
| $2,732 | $3,208 | $(476) | (14.8)% |
Interest expense for the six months ended June 30, 2020 and 2019 was primarily related to outstanding borrowings under our credit facility.
Income Tax Expense
(in thousands)
| Six Months Ended June 30, 2020 | 2019 | Increase (Decrease) % Change | ||
|---|---|---|---|---|
| Income tax expense | $9,570 | $11,062 | $(1,492) | (13.5)% |
| Effective tax rate | 19.0% | 22.3% |
The decrease of effective tax rate was mainly attributable to lower enacted tax rates from several states, certain higher tax credits, and excess tax benefits from stock-based compensation.
FINANCIAL CONDITION
LIQUIDITY AND CAPITAL RESOURCES
(All amounts in thousands, except share and per share data)
We expect our operations to continue generating sufficient cash flow to fund working capital requirements and necessary capital investments. We are actively pursuing additional acquisition candidates. We could seek additional bank loans or access to financial markets to fund such acquisitions, our operations, working capital, necessary capital investments or other cash requirements should we deem it necessary to do so. During the six months ended June 30, 2020, there were no material changes outside the ordinary course of business in the specified contractual obligations set forth in our Annual Report on Form 10-K for the year ended December 31, 2019, except as follows:
Cash
Cash and cash equivalents increased to $76,407 at June 30, 2020 from $65,672 at December 31, 2019. At June 30, 2020, the Company had $41,398 of cash and cash equivalents held by foreign subsidiaries. It is our intention to permanently reinvest these funds in foreign operations by continuing to make additional plant related investments, and potentially invest in partnerships or acquisitions; therefore, we do not currently expect to repatriate these funds in order to fund U.S. operations or obligations. However, if these funds are needed for U.S. operations, we could be required to pay additional withholding taxes to repatriate these funds. Working capital was $195,902 at June 30, 2020 as compared to $162,688 at December 31, 2019, an increase of $33,214. Working capital reflects the payment of the 2019 declared dividend in 2020 of $16,704, net payments from the revolving debt of $30,000, and capital expenditures and intangible assets acquired of $13,265.
(in thousands)
| Six Months Ended June 30, 2020 | 2019 | Increase (Decrease) % Change | ||
|---|---|---|---|---|
| Cash flows provided by operating activities | $67,180 | $48,812 | $18,368 | 37.6% |
| Cash flows used in investing activities | (13,593) | (107,675) | 94,082 | 87.4% |
| Cash flows (used in) provided by financing activities | (42,927) | 46,294 | (89,221) | 192.7% |
32
Operating Activities
Cash flows from operating activities provided $67,180 for the six months ended June 30, 2020 as compared to $48,812 for the six months ended June 30, 2019. The increase in cash flows from operating activities was primarily due to increased earnings, beneficial deferment of tax payments due to the CARES Act, and working capital changes.
Investing Activities
We continue to invest in corporate projects, improvements across all production facilities, and intangible assets. Total investments in property, plant and equipment and intangible assets were $13,265 and $14,714 for the six months ended June 30, 2020 and 2019, respectively. Cash paid for the Chemogas acquisition, net of cash acquired, amounted to $94,690 for the six months ended June 30, 2019. There were no acquisitions during the six months ended June 30, 2020.
Financing Activities
Net payments on the revolving loan amounted to $30,000 during the six months ended June 30, 2020 and we have $281,431 available under the credit agreement as of June 30, 2020.
We have an approved stock repurchase program. The total authorization under this program is 3,763,038 shares. Since the inception of the program in June 1999, a total of 2,464,272 shares have been purchased, and we had 109,919 shares remaining in treasury at June 30, 2020. We intend to acquire shares from time to time at prevailing market prices if and to the extent we deem it is advisable to do so based on our assessment of corporate cash flow, market conditions and other factors. The Company also repurchases shares from employees in connection with settlement of transactions under the Company's equity incentive plans.
Proceeds from stock options exercised were $6,802 and $1,809 for the six months ended June 30, 2020 and 2019, respectively. Dividend payments were $16,704 and $15,135 for the six months ended June 30, 2020 and 2019, respectively.
Other Matters Impacting Liquidity
We currently provide postretirement benefits in the form of two retirement medical plans, as discussed in Note 15 – Employee Benefit Plans. The liability recorded in other long-term liabilities on the consolidated balance sheets as of June 30, 2020 and December 31, 2019 was $1,123 and $1,076, respectively, and the plans are not funded. Historical cash payments made under these plans have typically been less than $100 per year. We do not anticipate any changes to the payments made in the current year for the plans.
On June 1, 2018, we established an unfunded, nonqualified deferred compensation plan maintained for the benefit of a select group of management or highly compensated employees. Assets of the plan are held in a rabbi trust, which are subject to additional risk of loss in the event of bankruptcy or insolvency of the Company. The deferred compensation liability as of June 30, 2020 and December 31, 2019 was $3,044 and $1,982, respectively, and was included in other long-term obligations on our balance sheet. The related rabbi trust assets were $3,046 and $1,982 as of June 30, 2020 and December 31, 2019, respectively, and were included in other non-current assets on the balance sheets.
Chemogas has an unfunded defined benefit plan. The plan provides for the payment of a lump sum at retirement or payments in case of death of the covered employees. The amount recorded for these obligations on our balance sheets as of June 30, 2020 and December 31, 2019 were both $596, and were included in other long-term obligations.
Critical Accounting Policies
There were no changes to the Company's Critical Accounting Policies, as described in its December 31, 2019 Annual Report on Form 10-K, during the six months ended June 30, 2020.
Related Party Transactions
We were engaged in related party transactions with St. Gabriel CC Company, LLC during the three and six months ended June 30, 2020. Refer to Note 18, "Related Party Transactions".
Market risk
As filed, 2,690 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Our cash and cash equivalents are held primarily in certificates of deposit and money market investment funds. In the second quarter of 2019, we entered into an interest rate swap and cross-currency swap for hedging purposes. Refer to details noted above (see Note 20). Additionally, as of June 30, 2020, our borrowings were under a revolving loan bearing interest at a fluctuating rate as defined by the Credit Agreement plus an applicable rate. The applicable rate is based upon our consolidated net leverage ratio, as defined in the Credit Agreement. A 100 basis point increase or decrease in interest rates, applied to our borrowings at June 30, 2020, would result in an increase or decrease in annual interest expense and a corresponding reduction or increase in cash flow of approximately $2,186. We are exposed to commodity price risks, including prices of our primary raw materials. Our objective is to seek a reduction in the potential negative earnings impact of raw material pricing arising in our business activities. We manage these financial exposures, where possible, through pricing and operational means. Our practices may change as economic conditions change. Additionally, as disclosed below in Item 1A, we are monitoring market risks related to the current COVID-19 pandemic very closely.
Interest Rate Risk
We have exposure to market risk for changes in interest rates, including the interest rate relating to our credit agreement dated June 27, 2018. In the second quarter of 2019, we began to manage our interest rate exposure through the use of derivative instruments. All of our derivative instruments are utilized for risk management purposes, and are not used for trading or speculative purposes. We have hedged a portion of our floating interest rate exposure using an interest rate swap (see Note 20 to our consolidated financial statements). As of June 30, 2020, the notional amount of our outstanding interest rate swap was $108,569.
Foreign Currency Exchange Risk
The financial condition and results of operations of our foreign subsidiaries are reported in Euros, Canadian Dollars, Malaysian Ringgits, Singapore Dollars, Australian Dollars, and Philippine Pesos and then translated into U.S. dollars at the applicable currency exchange rate for inclusion in our consolidated financial statements. Therefore, we are exposed to foreign currency exchange risk related to these currencies. Specifically, we are exposed to changes in exchange rates between the U.S. dollar and Euro. In the second quarter of 2019, we entered into a cross-currency swap, with a notional amount of $108,569, which we designated as a hedge of our net investment in Chemogas.
Controls and procedures
As filed, 2,047 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
(a) Evaluation of Disclosure Controls and Procedures
Prior to filing this report, we completed an evaluation under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rule 13a-15(e) of the Exchange Act as of June 30, 2020. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2020.
(b) Changes in Internal Controls
On May 27, 2019, we acquired Chemogas. As of June 30, 2020, management's assessment of and conclusion of the effectiveness of our internal controls over financial reporting of Chemogas have been completed. Therefore, management's assessment of and conclusion of the effectiveness of our internal control over financial reporting also includes the internal controls over financial reporting of Chemogas.
Other than the changes mentioned above, there have been no changes in the internal controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Act) during the fiscal quarter ended June 30, 2020, that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.
We completed the Zumbro acquisition in December 2019. Management’s assessment of and conclusion on the effectiveness of our internal control over financial reporting excludes the internal controls over financial reporting of Zumbro. Registrants are permitted to exclude acquisitions from their assessment of internal controls over financial reporting during the first year if, among other circumstances and factors, there is not adequate time between the consummation date of the acquisition and the assessment date for assessing internal controls. Management is in the process of implementing internal control procedures for this subsidiary.
Risk factors
As filed, 2,783 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
There have been no material changes in the Risk Factors identified in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, except as follows:
Our business, results of operations, financial condition, cash flows and stock price can be adversely affected by pandemics, epidemics or other public health emergencies, such as the recent outbreak of COVID-19.
Our business, results of operations, financial condition, cash flows and stock price can be adversely affected by pandemics, epidemics or other public health emergencies, such as the recent global outbreak of COVID-19. In March 2020, the World Health Organization characterized COVID-19 as a pandemic, and the President of the United States declared the COVID-19 outbreak a national emergency. The outbreak has resulted in governments around the world implementing increasingly stringent measures to help control the spread of the virus, including quarantines, "shelter in place" and "stay at home" orders, travel restrictions, business curtailments, school closures, and other measures. In addition, government and central banks in several parts of the world have enacted fiscal and monetary stimulus measures to counteract the impacts of COVID-19.
Our businesses have been deemed "essential" under the orders issued by federal, state and local governments. Although we have continued to operate our facilities to date consistent with federal guidelines and state and local orders, the outbreak of COVID-19 or similar viruses and any preventive or protective actions taken by governmental authorities may have a material adverse effect on our operations, supply chain, customers, and transportation networks, including business shutdowns or disruptions. The extent to which viruses such as COVID-19 may adversely impact our business depends on future developments, which are highly uncertain and unpredictable, depending upon the severity and duration of the outbreak and the effectiveness of actions taken globally to contain or mitigate their effects. Any resulting financial impact cannot be estimated reasonably at this time, but may materially adversely affect our business, results of operations, financial condition and cash flows. Additionally, concerns over the economic impact of COVID-19 have caused extreme volatility in financial and other capital markets which has and may continue to adversely impact our stock price and may affect our ability to access capital markets. To the extent the COVID-19 pandemic adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in our 2019 Annual Report. We will continue to implement mitigation strategies as needed to protect the long-term sustainability of our company.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-04-01 to 2020-06-30 | $173.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2020-01-01 to 2020-06-30 | $347.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2020-04-01 to 2020-06-30 | $118.0m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2020-01-01 to 2020-06-30 | $237.1m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2020-04-01 to 2020-06-30 | $55.4m | us-gaap:GrossProfit |
| Gross profit | 6 months2020-01-01 to 2020-06-30 | $110.7m | us-gaap:GrossProfit |
| Research and development | 3 months2020-04-01 to 2020-06-30 | $2.6m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2020-01-01 to 2020-06-30 | $5.3m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2020-04-01 to 2020-06-30 | $26.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2020-01-01 to 2020-06-30 | $53.2m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2020-04-01 to 2020-06-30 | $4.8m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2020-01-01 to 2020-06-30 | $9.6m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2020-04-01 to 2020-06-30 | $21.1m | us-gaap:NetIncomeLoss |
| Net income | 6 months2020-01-01 to 2020-06-30 | $40.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2020-04-01 to 2020-06-30 | $0.65 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2020-01-01 to 2020-06-30 | $1.26 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2020-04-01 to 2020-06-30 | $0.66 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2020-01-01 to 2020-06-30 | $1.27 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2020-04-01 to 2020-06-30 | 32,470,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2020-01-01 to 2020-06-30 | 32,492,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2020-01-01 to 2020-06-30 | $67.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2020-01-01 to 2020-06-30 | $12.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 6 months2020-01-01 to 2020-06-30 | $16.7m | us-gaap:PaymentsOfDividends |
| Share repurchases | 6 months2020-01-01 to 2020-06-30 | $3.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2020-06-30 | $76.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-06-30 | $263.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-06-30 | $1.15bn | us-gaap:Assets |
| Current liabilities | At period end2020-06-30 | $68.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-06-30 | $358.7m | us-gaap:Liabilities |
| Shareholders' equity | At period end2020-06-30 | $792.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-20-011128. Last ingested by Listed: Oct 24, 2026, 14:51 ET. Listed shows no prices and gives no investment advice.